zidesamtinib

FDA Drug Profile — JIDEYTRO

zidesamtinib is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including JIDEYTRO. Available dosage form: tablet, film coated.

Drug details

Generic Name
zidesamtinib
Brand Names
JIDEYTRO
Application Number
NDA220185
Sponsor
Patheon Inc.
NDC Codes
4
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
ZIDESAMTINIB

Indications and Usage

1 INDICATIONS AND USAGE JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor [see Dosage and Administration ( 2.1 ), Clinical Studies ( 14.1 )] . JIDEYTRO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor.( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.